Caribou Biosciences Securities Class Action
Analysis based on 6 articles · First reported Jan 08, 2025 · Last updated Jan 22, 2025
The market is impacted by the class action lawsuit against Rachel Haurwitz, as it alleges securities fraud and misrepresentation of clinical results and financial stability. This could lead to a decrease in investor confidence and a potential decline in the stock price of Rachel Haurwitz.
Levi & Korsinsky has filed a class action securities lawsuit against Rachel Haurwitz, alleging that the company made false and misleading statements to investors. The lawsuit claims that Rachel Haurwitz overstated the safety, efficacy, and durability of its drug CB-010 for treating r/r B-NHL and/or LBCL, as well as its overall clinical results and commercial prospects. Additionally, the complaint alleges that Rachel Haurwitz was at significant risk of having insufficient cash and liquidity to fund its operations, including preclinical research. Investors who suffered losses between July 14, 2023, and July 16, 2024, have until February 24, 2025, to request to be appointed as lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard